Financial Ratios Ind-Swift Laboratories Limited Bombay S.E.
Stocks
INDSWFTLAB
INE915B01019
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 231.35 INR | -1.11% |
|
-6.11% | +162.33% |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.76 | 3.19 | 6.26 | 8.99 | -1.89 | |||||
Return on Total Capital | 4.23 | 3.65 | 7.32 | 10.79 | -2.44 | |||||
Return On Equity % | -0.51 | -0.36 | 7.42 | 52.18 | 25.24 | |||||
Return on Common Equity | -0.51 | -0.36 | 7.42 | 52.18 | 25.24 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 50.21 | 49.95 | 46.08 | 49.01 | 48.74 | |||||
SG&A Margin | 11.89 | 10.94 | 11.52 | 12.2 | 22.28 | |||||
EBITDA Margin % | 18.32 | 21.13 | 19.64 | 20.68 | -3.88 | |||||
EBITA Margin % | 12.24 | 8.78 | 14.93 | 16.58 | -7.81 | |||||
EBIT Margin % | 12.24 | 8.78 | 14.93 | 16.58 | -7.81 | |||||
Income From Continuing Operations Margin % | -0.35 | -0.2 | 3.91 | 32.45 | 44.59 | |||||
Net Income Margin % | -0.35 | -0.2 | 3.91 | 32.45 | 44.59 | |||||
Net Avail. For Common Margin % | -0.35 | -0.2 | 3.91 | 32.45 | 44.59 | |||||
Normalized Net Income Margin | 1.24 | 1.56 | 5.86 | 9.27 | 0.65 | |||||
Levered Free Cash Flow Margin | 2.7 | 2.56 | 3.62 | 75.91 | -37.38 | |||||
Unlevered Free Cash Flow Margin | 9.13 | 7.99 | 8.06 | 78.16 | -37.23 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.49 | 0.58 | 0.67 | 0.87 | 0.39 | |||||
Fixed Assets Turnover | 1.17 | 1.52 | 1.98 | 4.34 | 2.29 | |||||
Receivables Turnover (Average Receivables) | 2.15 | 2.34 | 2.51 | 3.8 | 2.35 | |||||
Inventory Turnover (Average Inventory) | 1.26 | 1.31 | 1.51 | 2.95 | 3.05 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3 | 3.22 | 3.14 | 2.99 | 3.92 | |||||
Quick Ratio | 1.56 | 1.54 | 1.48 | 2.76 | 3.05 | |||||
Operating Cash Flow to Current Liabilities | 0.43 | 0.45 | 0.52 | -0.74 | -0.12 | |||||
Days Sales Outstanding (Average Receivables) | 169.7 | 155.87 | 145.13 | 96.36 | 155.14 | |||||
Days Outstanding Inventory (Average Inventory) | 290.45 | 278.7 | 241.38 | 124.24 | 119.61 | |||||
Average Days Payable Outstanding | 103.27 | 99.14 | 104.16 | 233.71 | 224.59 | |||||
Cash Conversion Cycle (Average Days) | 356.88 | 335.43 | 282.35 | -13.12 | 50.16 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 166.61 | 158.61 | 126.42 | 1.78 | 3.48 | |||||
Total Debt / Total Capital | 62.49 | 61.33 | 55.83 | 1.75 | 3.37 | |||||
LT Debt/Equity | 146.6 | 141.18 | 110.44 | 1.2 | 2.21 | |||||
Long-Term Debt / Total Capital | 54.99 | 54.59 | 48.78 | 1.18 | 2.14 | |||||
Total Liabilities / Total Assets | 66.82 | 66.63 | 62.61 | 20.06 | 18.45 | |||||
EBIT / Interest Expense | 1.19 | 1.01 | 2.1 | 4.61 | -31.71 | |||||
EBITDA / Interest Expense | 1.78 | 2.43 | 2.77 | 5.75 | -15.75 | |||||
(EBITDA - Capex) / Interest Expense | 1.74 | 2.23 | 2.62 | 4.79 | -62.32 | |||||
Total Debt / EBITDA | 6.05 | 4.29 | 3.61 | 0.06 | -1.88 | |||||
Net Debt / EBITDA | 5.98 | 4.19 | 3.53 | -1.55 | 19.59 | |||||
Total Debt / (EBITDA - Capex) | 6.2 | 4.67 | 3.81 | 0.07 | -0.47 | |||||
Net Debt / (EBITDA - Capex) | 6.13 | 4.57 | 3.73 | -1.86 | 4.95 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 13.44 | 16.03 | 15.48 | 6.69 | -67.14 | |||||
Gross Profit, 1 Yr. Growth % | 13.07 | 15.42 | 8.7 | 13.46 | -67.38 | |||||
EBITDA, 1 Yr. Growth % | 1.27 | 12.16 | 6.89 | 12.33 | -107.11 | |||||
EBITA, 1 Yr. Growth % | 50.03 | -16.72 | 96.4 | 18.46 | -119.41 | |||||
EBIT, 1 Yr. Growth % | 50.03 | -16.72 | 96.4 | 18.46 | -119.42 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -85.15 | -31.72 | -2.31K | 784.44 | -53.51 | |||||
Net Income, 1 Yr. Growth % | -85.15 | -31.72 | -2.31K | 784.44 | -53.51 | |||||
Normalized Net Income, 1 Yr. Growth % | -190.79 | 45.48 | 335.12 | 68.81 | -96.5 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -87.57 | -31.72 | -2.31K | 784.38 | -61.38 | |||||
Accounts Receivable, 1 Yr. Growth % | 9.07 | 5.18 | 11.11 | -66.53 | -47.43 | |||||
Inventory, 1 Yr. Growth % | 9.58 | 14.06 | 2.36 | -97.62 | 53.16 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -6.31 | -14.87 | -6.92 | -99.1 | 13.01 | |||||
Total Assets, 1 Yr. Growth % | -2.76 | -0.97 | 1.29 | -36.13 | -1.51 | |||||
Tangible Book Value, 1 Yr. Growth % | -0.92 | 0.98 | 13.66 | 36.59 | 45.01 | |||||
Common Equity, 1 Yr. Growth % | -5.8 | -0.42 | 13.47 | 36.59 | 44.44 | |||||
Cash From Operations, 1 Yr. Growth % | 7.75 | 11.36 | 29.51 | -183.81 | -86.38 | |||||
Capital Expenditures, 1 Yr. Growth % | -63.6 | 370.92 | -30.65 | 248.59 | -11.79 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -0.1 | 10 | 57.48 | 2.14K | -122.79 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -6.46 | 1.52 | 15.14 | 935.12 | -121.29 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 7.89 | 14.73 | 15.8 | 11 | -32.03 | |||||
Gross Profit, 2 Yr. CAGR % | 10.09 | 14.24 | 10.93 | 11.06 | -30.1 | |||||
EBITDA, 2 Yr. CAGR % | 5.75 | 16.44 | 9.76 | 9.58 | -69.81 | |||||
EBITA, 2 Yr. CAGR % | 57.93 | 11.78 | 27.9 | 52.53 | -50.85 | |||||
EBIT, 2 Yr. CAGR % | 57.93 | 11.78 | 27.9 | 52.53 | -50.85 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -67.03 | -68.15 | 288.89 | 1.3K | 129.4 | |||||
Net Income, 2 Yr. CAGR % | -67.03 | -68.15 | 288.89 | 1.3K | 129.4 | |||||
Normalized Net Income, 2 Yr. CAGR % | -26.38 | 14.92 | 151.6 | 171.03 | -77.4 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -70.11 | -70.86 | 288.89 | 1.3K | 109.07 | |||||
Accounts Receivable, 2 Yr. CAGR % | 11.01 | 7.11 | 8.1 | -39.02 | -42.94 | |||||
Inventory, 2 Yr. CAGR % | 8.93 | 11.8 | 8.05 | -84.38 | -48.98 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -5.9 | -10.69 | -10.99 | -90.82 | -33.76 | |||||
Total Assets, 2 Yr. CAGR % | -2.78 | -1.87 | 0.15 | -19.56 | -11.2 | |||||
Tangible Book Value, 2 Yr. CAGR % | 7.75 | 0.03 | 7.14 | 24.6 | 30.55 | |||||
Common Equity, 2 Yr. CAGR % | 1.33 | -3.15 | 6.3 | 24.5 | 31.15 | |||||
Cash From Operations, 2 Yr. CAGR % | 44.76 | 9.54 | 20.09 | 4.18 | -63.82 | |||||
Capital Expenditures, 2 Yr. CAGR % | -49.37 | 30.92 | 80.72 | 55.48 | 124.57 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -52.7 | 4.83 | 34.09 | 493.94 | 118.54 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 20.72 | -2.55 | 8.77 | 245.24 | 46.1 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 5.29 | 10.54 | 15.01 | 12.68 | -18.9 | |||||
Gross Profit, 3 Yr. CAGR % | 5.63 | 11.84 | 11.64 | 11.77 | -19.02 | |||||
EBITDA, 3 Yr. CAGR % | 3.74 | 14.4 | 13.35 | 10.61 | -53.98 | |||||
EBITA, 3 Yr. CAGR % | 21.32 | 27.59 | 34.89 | 24.68 | -22 | |||||
EBIT, 3 Yr. CAGR % | 21.32 | 27.59 | 34.89 | 24.68 | -22 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -47.68 | -57.97 | 30.97 | 411.41 | 388.48 | |||||
Net Income, 3 Yr. CAGR % | -47.68 | -57.97 | 30.97 | 411.41 | 388.48 | |||||
Normalized Net Income, 3 Yr. CAGR % | -21.98 | -7.61 | 79.12 | 120.26 | -39.44 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -52.2 | -60.64 | 23.43 | 411.4 | 359.17 | |||||
Accounts Receivable, 3 Yr. CAGR % | 1.97 | 9.03 | 8.42 | -26.87 | -28.75 | |||||
Inventory, 3 Yr. CAGR % | 5.83 | 10.61 | 8.56 | -69.69 | -35.65 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -4.7 | -8.99 | -9.45 | -80.72 | -25.81 | |||||
Total Assets, 3 Yr. CAGR % | -3.49 | -2.18 | -0.83 | -13.79 | -7.22 | |||||
Tangible Book Value, 3 Yr. CAGR % | 11.61 | 5.45 | 4.38 | 16.17 | 24.66 | |||||
Common Equity, 3 Yr. CAGR % | 2.94 | 0.74 | 2.1 | 15.57 | 24.97 | |||||
Cash From Operations, 3 Yr. CAGR % | 22.68 | 32.64 | 15.83 | 6.52 | -44.66 | |||||
Capital Expenditures, 3 Yr. CAGR % | -42.39 | 6.47 | 5.93 | 124.96 | 51.79 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -35.12 | -37.33 | 21.56 | 242.78 | 95.93 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -8.01 | 13.95 | 3.44 | 130.5 | 34.95 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 6.43 | 8.06 | 9.37 | 10.74 | -6.81 | |||||
Gross Profit, 5 Yr. CAGR % | 7.91 | 10.29 | 7.72 | 11.1 | -7.43 | |||||
EBITDA, 5 Yr. CAGR % | 7.05 | 12.62 | 9.93 | 12.55 | -33.22 | |||||
EBITA, 5 Yr. CAGR % | 27.14 | 21.78 | 23.91 | 37.04 | -9.93 | |||||
EBIT, 5 Yr. CAGR % | 27.14 | 21.78 | 23.91 | 37.04 | -9.92 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -44.3 | -44.03 | 16.71 | 70.82 | 63.88 | |||||
Net Income, 5 Yr. CAGR % | -44.3 | -44.03 | 16.71 | 70.82 | 63.88 | |||||
Normalized Net Income, 5 Yr. CAGR % | -23.71 | -12.1 | 24.62 | 42.09 | -21.75 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -48.24 | -47.59 | 10.56 | 64.23 | 52.39 | |||||
Accounts Receivable, 5 Yr. CAGR % | 3.03 | 4.94 | 4.38 | -13.58 | -16.13 | |||||
Inventory, 5 Yr. CAGR % | 1.08 | 4.52 | 6.72 | -49.44 | -19.74 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -4.58 | -6.54 | -7.26 | -63.65 | -20.1 | |||||
Total Assets, 5 Yr. CAGR % | -3.86 | -3.37 | -2.05 | -9.54 | -5.11 | |||||
Tangible Book Value, 5 Yr. CAGR % | 15.51 | 13.06 | 9.8 | 12.73 | 14.16 | |||||
Common Equity, 5 Yr. CAGR % | 3.13 | 2.49 | 4.27 | 9.64 | 12.86 | |||||
Cash From Operations, 5 Yr. CAGR % | 11.18 | 9.48 | 21.64 | 20.43 | -27.28 | |||||
Capital Expenditures, 5 Yr. CAGR % | -31.31 | -1.83 | -8.99 | 23.89 | 43.07 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 6.25 | -35.08 | -13.26 | 55.22 | 53.7 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 2.06 | -21.38 | -1.63 | 77.96 | 18.76 |
Select your edition
All financial news and data tailored to specific country editions
















